Alpha-synuclein intron 1 (SNCA intron 1) (SNCA intron 1)

Alpha-synuclein intron 1 (SNCA intron 1) is a critical regulatory region within the SNCA gene that contains a CpG island responsible for controlling the gene's expression levels. In healthy individuals, this region is typically methylated, which helps maintain physiological levels of the alpha-synuclein protein. However, hypomethylation of SNCA intron 1 has been strongly linked to the overproduction of alpha-synuclein, a hallmark of Parkinson's disease and other synucleinopathies (Jowaed et al., 2010; PubMed: 20164367). Because elevated levels of alpha-synuclein lead to toxic aggregation and neuronal death, this genomic region has emerged as a novel therapeutic target for epigenetic modulation. Experimental approaches, such as using CRISPR-dCas9 fused with DNA methyltransferases (e.g., DNMT3A), aim to restore methylation at this site to downregulate SNCA expression (Kantor et al., 2018; PubMed: 29743447). Successfully targeting SNCA intron 1 could provide a precision medicine approach to slow or halt the progression of neurodegenerative diseases by addressing the root cause of protein overexpression. Current research focuses on optimizing delivery methods to the central nervous system and ensuring the specificity of these epigenetic interventions.

Other names

SNCA-i1SNCA CpG islandAlpha-synuclein gene regulatory element

Targeted DNA methylation to repress gene transcription and reduce alpha-synuclein protein levels.